Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Systemic Sclerosis (Scleroderma) 29
May 25, 2016: Cytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial 29
May 17, 2016: European Scleroderma Trial Investigating Cytori Cell Therapy to Be Presented in Japan 29
Apr 27, 2016: Cytori Announces Timing for Full Enrollment in U.S. Phase III Scleroderma Trial 30
Apr 12, 2016: Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis 30
Mar 24, 2016: Cytori provides Update on Its U.S. Phase III Scleroderma Trial 31
Mar 15, 2016: ProMetic announces the addition of scleroderma to PBI-4050 targeted indications 31
Clinical Trial Profile Snapshots 33
Appendix 202
Abbreviations 202
Definitions 202
Research Methodology 203
Secondary Research 203
About GlobalData 204
Contact Us 204
Disclaimer 204
Source 205
List of Tables
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, G7 Countries (%), 2016* 14
Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, E7 Countries (%), 2016* 17
Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Systemic Sclerosis (Scleroderma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
List of Figures
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, G7 Countries (%), 2016* 14
Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, E7 Countries (%), 2016* 17
Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Systemic Sclerosis (Scleroderma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 203